Skip Navigation

Annals of Oncology 2007 18(8):1287; doi:10.1093/annonc/mdm416
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Impact of FDG-PET in staging breast cancer
 
Positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) has proven to be accurate for the staging of breast cancer with sensitivities and specificities of 93% and 75%, respectively, for primary staging, and 89-100% and 72-88%, respectively, for detection and restaging of recurrent breast cancer. However, data regarding the clinical impact of PET in the primary staging of breast cancer are rare. In this issue, Klaeser et al. report on a . . . [Full Text of this Article]


   Docetaxel and oxaliplatin in ovarian cancer
 

   VAD-doxil vs. VAD-doxil plus thalidomide for multiple myeloma
 

   Prognosis for long-term survivors of cancer
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?